Creatinine-to-bodyweight ratio is a predictor of incident non-alcoholic fatty liver disease: A population-based longitudinal study.
cohort study
creatinine-to-bodyweight ratio
epidemiology
fatty liver disease
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
28
04
2019
revised:
27
08
2019
accepted:
17
09
2019
pubmed:
7
11
2019
medline:
7
11
2019
entrez:
7
11
2019
Statut:
ppublish
Résumé
Serum creatinine (Cre) is used as a surrogate marker of muscle mass. We investigated the impact of the Cre-to-bodyweight (BW) ratio (Cre/BW) on incident non-alcoholic fatty liver disease (NAFLD). Fatty liver disease was diagnosed by abdominal ultrasonography. In this historical cohort study of 13 728 participants (6397 men and 7331 women), we divided the participants into two groups by sex and into quartiles according to Cre (mg/dL)/BW (kg; Q1-4). We carried out Cox proportional hazard models, adjusting for age, alanine aminotransferase, fasting plasma glucose, systolic blood pressure, alcohol consumption, smoking status, and exercise. During the 5.1-year follow up for men and 6.0-year follow up for women, 2497 participants (1696 men, 801 women) developed NAFLD. The 4000-days cumulative incidence rates of FLD for men and women were 29.6% and 16.6% in Q1, 28.2% and 10.6% in Q2, 25.5% and 8.8% in Q3, and 22.7% and 7.7% in Q4, respectively. The hazard ratios of incident NAFLD in Q1 (Cre/BW [×100]: men <1.28; women <1.17) were 1.89 (95% confidence interval 1.64-2.17, P < 0.001) in men and 2.96 (2.42-3.62, P < 0.001) in women, compared with Q4 (Cre/BW [×100]: men ≥1.61; women ≥1.51). A low Cre/BW is associated with an increased risk of NAFLD. Screening Cre/BW can be used to identify individuals who are at high risk of NAFLD.
Types de publication
Journal Article
Langues
eng
Pagination
57-66Informations de copyright
© 2019 The Japan Society of Hepatology.
Références
Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2017; 15: 11-20. https://doi.org/10.1038/nrgastro.2017.109.
Lonardo A, Bellentani S, Argo CK et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015; 47: 997-1006. https://doi.org/10.1016/j.dld.2015.08.004.
Hashimoto Y, Hamaguchi M, Fukuda T, Ohbora A, Kojima T, Fukui M. Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals. Endocrine 2017; 57: 89-97. https://doi.org/10.1007/s12020-017-1313-6.
Fukuda T, Hamaguchi M, Kojima T et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016; 36: 275-283. https://doi.org/10.1111/liv.12912.
Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: A population-based longitudinal study. Int J Obes (Lond) 2019; 43: 139-148. https://doi.org/10.1038/s41366-018-0076-3.
Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study. Medicine (Baltimore) 2017; 96: e6712. https://doi.org/10.1097/MD.0000000000006712.
Kaji A, Hashimoto Y, Kobayashi Y et al. Sarcopenia is associated with tongue pressure in older patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort study. Geriatr Gerontol Int 2019; 19: 153-158. https://doi.org/10.1111/ggi.13577.
Delmonico MJ, Harris TB, Lee JS et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc 2007; 55: 769-774. https://doi.org/10.1111/j.1532-5415.2007.01140.x.
Goodpaster BH, Park SW, Harris TB et al. The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006; 61: 1059-1064.
Hashimoto Y, Kaji A, Sakai R et al. Sarcopenia is associated with blood pressure variability in older patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort study. Geriatr Gerontol Int 2018; 18: 1345-1349. https://doi.org/10.1111/ggi.13487.
Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG. Sarcopenic obesity and risk of cardiovascular disease and mortality: A population-based cohort study of older men. J Am Geriatr Soc 2014; 62: 253-260. https://doi.org/10.1111/jgs.12652.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on sarcopenia in older people. Age Ageing 2010; 39: 412-423. https://doi.org/10.1093/ageing/afq034.
Moon SS. Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: The Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010. Endocr J 2014; 61: 61-70.
Okamura T, Miki A, Hashimoto Y et al. Shortage of energy intake rather than protein intake is associated with sarcopenia in elderly patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort. J Diabetes 2018. https://doi.org/10.1111/1753-0407.12874.
Kim M, Shinkai S, Murayama H, Mori S. Comparison of segmental multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body composition in a community-dwelling older population. Geriatr Gerontol Int 2015; 15: 1013-1022. https://doi.org/10.1111/ggi.12384.
Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S. Measurement of muscle mass in humans: Validity of the 24-hour urinary creatinine method. Am J Clin Nutr 1983; 37: 478-494. https://doi.org/10.1093/ajcn/37.3.478.
Baxmann AC, Ahmed MS, Marques NC et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008; 3: 348-354. https://doi.org/10.2215/CJN.02870707.
Harita N, Hayashi T, Sato KK et al. Lower serum creatinine is a new risk factor of type 2 diabetes: The Kansai Healthcare Study. Diabetes Care 2009; 32: 424-426. https://doi.org/10.2337/dc08-1265.
Kashima S, Inoue K, Matsumoto M, Akimoto K. Low serum creatinine is a type 2 diabetes risk factor in men and women: The Yuport Health Checkup Center cohort study. Diabetes Metab 2017; 43: 460-464. https://doi.org/10.1016/j.diabet.2017.04.005.
Koo BK, Kim D, Joo SK et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 2017; 66: 123-131. https://doi.org/10.1016/j.jhep.2016.08.019.
Hashimoto Y, Osaka T, Fukuda T, Tanaka M, Yamazaki M, Fukui M. The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes. Endocr J 2016; 63: 877-884. https://doi.org/10.1507/endocrj.EJ16-0124.
Osaka T, Hashimoto Y, Fukuda T, Tanaka M, Yamazaki M, Fukui M. Relationship between skeletal muscle mass and hepatic fibrosis in patients with type 2 diabetes. Diabetes Metab 2017; 43: 184-186. https://doi.org/10.1016/j.diabet.2016.07.035.
Seko Y, Mizuno N, Okishio S et al. Clinical and pathological features of sarcopenia-related indices in patients with non-alcoholic fatty liver disease. Hepatol Res 2019:hepr.13321. https://doi.org/10.1111/hepr.13321.
Kim G, Lee SE, Lee YB et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study. Hepatology 2018; 68: 1755-1768. https://doi.org/10.1002/hep.30049.
Takamura T, Kita Y, Nakagen M et al. Weight-adjusted lean body mass and calf circumference are protective against obesity-associated insulin resistance and metabolic abnormalities. Heliyon 2017; 3: e00347. https://doi.org/10.1016/j.heliyon.2017.e00347.
Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728.
Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Low urine pH is a risk for non-alcoholic fatty liver disease: A population-based longitudinal study. Clin Res Hepatol Gastroenterol 2018. https://doi.org/10.1016/j.clinre.2018.06.005.
Hu H, Nakagawa T, Honda T et al. Low serum creatinine and risk of diabetes: The Japan Epidemiology Collaboration on Occupational Health Study. J Diabetes Investig 2019. https://doi.org/10.1111/jdi.13024.
Okamura T, Hashimoto Y, Hamaguchi M, Ohbora A, Kojima T, Fukui M. Metabolically healthy obesity and risk of leukoaraiosis; a population based cross-sectional study. Endocr J 2018; 65: 669-675. https://doi.org/10.1507/endocrj.EJ18-0023.
Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. Glutamyltransferase as a Predictor of Chronic Kidney Disease in Nonhypertensive and Nondiabetic Korean Men. Clin Chem 2006; 53: 71-77. https://doi.org/10.1373/clinchem.2006.078980.
Hamaguchi M, Kojima T, Itoh Y et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-2715. https://doi.org/10.1111/j.1572-0241.2007.01526.x.
Miyake T, Kumagi T, Furukawa S et al. Short sleep duration reduces the risk of nonalcoholic fatty liver disease onset in men: A community-based longitudinal cohort study. J Gastroenterol 2015; 50: 583-589. https://doi.org/10.1007/s00535-014-0989-0.
Hashimoto Y, Hamaguchi M, Kojima T et al. The modest alcohol consumption reduces the incidence of fatty liver in men: A population-based large-scale cohort study. J Gastroenterol Hepatol 2015; 30: 546-552. https://doi.org/10.1111/jgh.12786.
Fukuda Y, Hashimoto Y, Hamaguchi M et al. Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int 2016; 36: 713-720. https://doi.org/10.1111/liv.12977.
Peng TC, Wu LW, Chen WL, Liaw FY, Chang YW, Kao TW. Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition. Clin Nutr 2019; 38: 422-428. https://doi.org/10.1016/j.clnu.2017.11.021.
Hashimoto Y, Hamaguchi M, Fukuda T et al. BMI history and risk of incident fatty liver: A population-based large-scale cohort study. Eur J Gastroenterol Hepatol 2016; 28: 1188-1193. https://doi.org/10.1097/MEG.0000000000000682.
Lee SW, Youm Y, Lee WJ et al. Appendicular skeletal muscle mass and insulin resistance in an elderly korean population: The korean social life, health and aging project-health examination cohort. Diabetes Metab J 2015; 39: 37-45. https://doi.org/10.4093/dmj.2015.39.1.37.
Boström P, Wu J, Jedrychowski MP et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468. https://doi.org/10.1038/nature10777.
Miller AM, Wang H, Bertola A et al. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 2011; 54: 846-856. https://doi.org/10.1002/hep.24517.
Zhang HJ, Zhang XF, Ma ZM et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2013; 59: 557-562. https://doi.org/10.1016/j.jhep.2013.04.030.
Seo JA, Cho H, Eun CR et al. Association between visceral obesity and sarcopenia and vitamin D deficiency in older koreans: The Ansan Geriatric Study. J Am Geriatr Soc 2012; 60: 700-706. https://doi.org/10.1111/j.1532-5415.2012.03887.x.
Yin Y, Yu Z, Xia M, Luo X, Lu X, Ling W. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur J Clin Invest 2012; 42: 1189-1196. https://doi.org/10.1111/j.1365-2362.2012.02706.x.
Roth CL, Elfers CT, Figlewicz DP et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology 2012; 55: 1103-1111. https://doi.org/10.1002/hep.24737.
Geier A. Shedding new light on vitamin D and fatty liver disease. J Hepatol 2011; 55: 273-275. https://doi.org/10.1016/j.jhep.2010.12.026.
Hong HC, Hwang SY, Choi HY et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study. Hepatology 2014; 59: 1772-1778. https://doi.org/10.1002/hep.26716.
Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care 2012; 15: 12-22. https://doi.org/10.1097/MCO.0b013e32834dd297.
Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - The link between adipocytes and hepatocytes. Digestion 2011; 83: 124-133. https://doi.org/10.1159/000318741.